What amount sold does ProMed Investment Holdings, LLC report in Form D filings?

The latest linked filings report $4.4M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was ProMed Investment Holdings, LLC's most recent SEC filing?

ProMed Investment Holdings, LLC's most recent Form D filing was on 2016-01-29.

How many investors does ProMed Investment Holdings, LLC have?

The most recent Form D filing lists 44 investor(s).

What type of securities does ProMed Investment Holdings, LLC offer?

ProMed Investment Holdings, LLC's SEC Form D filings indicate equity offerings.

ProMed Investment Holdings, LLC

CIK: 0001665044·Biotechnology·CHICAGO, IL·Limited Liability Company·Founded 2015

Reported Sold

$4,400,000

Total Filings

Identified Offerings

Last Filed

Jan 29, 2016

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jan 29, 2016Form D — New notice

Reported sold: $4,400,000 · Target: $4,400,000

Rule 506(b)·44 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 1 identified offering

$4,400,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Promus Equity Partners, LLC

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jan 29, 2016	New	$4,400,000	$4,400,000	44

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

BioLattice Ophthalmics, Inc,

Biotechnology

Offering target: $3,310,000

Filed Oct 28, 2026